Iodine I 131 Monoclonal Antibody TNT-1/B in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
Completed · Phase 1
Conditions studied: Brain and Central Nervous System Tumors
In brief
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody TNT-1/B (\^131I MOAB TNT-1/B), can find tumor cells and carry tumor-killing substances to them without harming normal cells. This may be an effective treatment for glioblastoma multiforme. PURPOSE: This phase I trial is studying the side effects and best dose of \^131I MOAB TNT-1/B in treating patients with progressive or recurrent glioblastoma multiforme.
Key facts
- Study ID
- NCT00128635
- Run by
- Abramson Cancer Center at Penn Medicine
- People needed
- 22
- Starts
- 2005-10-01
- Expected to finish
- 2007-10-01
- Last updated by the study team
- 2016-02-19
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham — Birmingham, Alabama, United States
- Winship Cancer Institute of Emory University — Atlanta, Georgia, United States
- Wake Forest University Comprehensive Cancer Center — Winston-Salem, North Carolina, United States
- Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.